Close Menu

NEW YORK ─ Ahrensburg, Germany-based Abviris, the developer of a lateral flow test for cancer detection, said on Tuesday that it has raised almost €2 million ($2.4 million) in financing to expand its business.

Current investor High-Tech Gründerfonds, a venture capital investment firm based in Bonn, Germany, was the "the most significant" investor in the financing, a company representative said in an email, declining to name the other investors in the financing.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
08
Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.